DWM
RXRX icon

Dakota Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Dakota Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,438
Closed -$104K – 643
2022
Q4 		$104K Sell
13,438
-13,463
-50% -$132K 0.01% 584
2022
Q3 		$286K Buy
+26,901
New +$272K 0.02% 433

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Dakota Wealth Management's RXRX Position: Q1 2023 in Review

Dakota Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2023, closing a stake of 13,438 shares — an estimated $104K sold.

Dakota Wealth Management first reported a position in RXRX in Q3 2022 and held it in 2 quarters. The position peaked at $286K in Q3 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q1 2023.

  • Dakota Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Dakota Wealth Management sold 13,438 Recursion Pharmaceuticals shares in Q1 2023, an estimated $104K.
  • Dakota Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Dakota Wealth Management's Recursion Pharmaceuticals position peaked at $286K in Q3 2022.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2023.

Based on Dakota Wealth Management's 13F filing for Q1 2023, filed 14 Apr 2023.